Latest publications
A validated prognostic nomogram for patients with newly diagnosed lower-grade gliomas in a large-scale Asian cohort.
- NORLUX Neuro-Oncology Laboratory
2020 May. Neuro Oncol.22(5):729-731.
Dual blockade of STAT3 and EGFR: a key to unlock drug resistance in glioblastoma?
- NORLUX Neuro-Oncology Laboratory
2020 Apr. Neuro Oncol.22(4):440-441.
BCL2L15 (BCL2-like 15).
- NORLUX Neuro-Oncology Laboratory
2020 Apr. Atlas of Genetics and Cytogenetics in Oncology and Haematology.24(12):445-450.
Reduced expression of proteolipid protein 2 increases ER stress-induced apoptosis and autophagy in glioblastoma.
- NORLUX Neuro-Oncology Laboratory
2020 Mar. J Cell Mol Med.24(5):2847-2856. Epub 2019 Nov 28.
Gender issues from the perspective of health-care professionals in Neuro-oncology: an EANO and EORTC Brain Tumor Group survey.
- NORLUX Neuro-Oncology Laboratory
2020 Mar. Neurooncol Pract.7(2):249-259. Epub 2020 Jan 10.
Fisetin protects against cardiac cell death through reduction of ROS production and caspases activity.
- Proteomics of Cellular Signaling
- Quantitative Biology Unit
- NORLUX Neuro-Oncology Laboratory
- Computational Biomedicine
2020 Feb. Sci Rep.10(1):2896.
Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects.
- NORLUX Neuro-Oncology Laboratory
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2020 Feb. Neurooncol Adv.2(1):vdaa013.
Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/beta-catenin signalling.
- NORLUX Neuro-Oncology Laboratory
2020 Feb. Brain.143(2):512-530.
Revealing and harnessing tumour-associated microglia/macrophage heterogeneity in glioblastoma.
- Neuro-Immunology Group
- NORLUX Neuro-Oncology Laboratory
2020 Jan. Int J Mol Sci.21(3):E689.
Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma.
- NORLUX Neuro-Oncology Laboratory
2020 Jan. EMBO Mol Med.12(1):e10924. Epub 2019 Nov 28.
PMEPA1 isoform a drives progression of glioblastoma by promoting protein degradation of the Hippo pathway kinase LATS1.
- NORLUX Neuro-Oncology Laboratory
2020 Jan. Oncogene.39(5):1125-1139. Epub 2019 Oct 11.
A new chance for EGFR inhibition in glioblastoma?
- NORLUX Neuro-Oncology Laboratory
2019 Dec. Neuro Oncol.21(12):1487-1488.
Mutant IDH1 differently affects redox state and metabolism in glial cells of normal and tumor origin.
- NORLUX Neuro-Oncology Laboratory
2019 Dec. Cancers.11(12):2028.
Spatially regularized estimation of the tissue homogeneity model parameters in DCE-MRI using proximal minimization.
- NORLUX Neuro-Oncology Laboratory
- Translational Radiomics
2019 Dec. Magn Reson Med.82(6):2257-2272. Epub 2019 Jul 17.
Longitudinal molecular trajectories of diffuse glioma in adults.
- NORLUX Neuro-Oncology Laboratory
2019 Dec. Nature.576(7785):112-120. Epub 2019 Nov 20.
Long Noncoding RNA SChLAP1 forms a Growth-Promoting Complex with HNRNPL in human glioblastoma through stabilization of ACTN4 and activation of NF-κB signaling.
- NORLUX Neuro-Oncology Laboratory
2019 Nov. Clin Cancer Res.25(22):6868-6881. Epub 2019 Sep 6.
Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood-brain barrier.
- Translational Radiomics
- NORLUX Neuro-Oncology Laboratory
2019 Nov. Mol Cancer Ther.18(11):2171-2181. Epub 2019 Aug 29.
The implication of anti-angiogenic treatment of malignancies on human metabolism. In Tumor angiogenesis: A key target for cancer therapy. (Book Chapter)
- NORLUX Neuro-Oncology Laboratory
2019 Oct. Marmé D, ed. Springer, 2019. p.661-672. ISBN 978-3-319-33671-8.
The invasive proteome of glioblastoma revealed by laser-capture microdissection.
- NORLUX Neuro-Oncology Laboratory
2019 Sep. Neurooncol Adv.1(1):vdz029.
The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma.
- NORLUX Neuro-Oncology Laboratory
- Multiomics Data Science
- Immuno-Pharmacology and Interactomics
2019 Sep. Neurooncol Adv.1(1):vdz024.